Eric Desauziers

Title: The Innovations of Eric Desauziers

Introduction

Eric Desauziers is a notable inventor based in Lyons, France. He has made significant contributions to the field of pneumococcal vaccine development. With a total of two patents to his name, his work focuses on enhancing the efficacy of vaccines against pneumococcal infections.

Latest Patents

Desauziers' latest patents include a multivalent pneumococcal polysaccharide-protein conjugate composition. This innovative composition comprises 20 different pneumococcal capsular polysaccharide-protein conjugates. Each conjugate includes a capsular polysaccharide from a different serotype conjugated to either tetanus toxoid or CRM. The selected serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Two of the capsular polysaccharides are conjugated to tetanus toxoid, while the remaining are conjugated to CRMig7. Additionally, he has developed another composition comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, following a similar methodology.

Career Highlights

Throughout his career, Desauziers has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Sanofi Pasteur Inc. and SK Bioscience Co., Ltd. His work has significantly impacted the development of vaccines aimed at preventing pneumococcal diseases.

Collaborations

Desauziers has collaborated with talented individuals in his field, including Kyungjun An and Wooyoung Choi. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Eric Desauziers is a distinguished inventor whose work in pneumococcal vaccine development has made a lasting impact. His innovative compositions and collaborations highlight his commitment to improving public health through effective vaccination strategies.